CIPRO XR
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
Dec 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Drug data last refreshed 5h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CIPRO XR is an extended-release oral tablet formulation of ciprofloxacin, a fluoroquinolone antibiotic approved by the FDA in December 2002. The drug treats bacterial infections across multiple indications via inhibition of bacterial DNA gyrase and topoisomerase IV. It is indicated for respiratory, urinary, and gastrointestinal tract infections in adult patients.
LOE Approaching
As LOE approaches, CIPRO XR brand teams face declining revenue and shrinking headcount; careers here increasingly focus on defensive tactics and managed transition strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Efficacy and Safety of CIPRO XR Versus CIPRO IR in Patients With Complicated Urinary Tract Infections
Started Mar 2004
212 enrolled
Urinary Tract Infection
A Phase IV Study of Cipro XR in Uncomplicated UTI
Started Feb 2003
7,614 enrolled
Urinary Tract Infections
Career Relevance
CIPRO XR currently has zero linked job openings, reflecting the product's late-stage lifecycle and limited team expansion. Careers on this asset prioritize defensive commercial strategies, generic containment, and transition management rather than growth or innovation.
Brand Manager
Worked on CIPRO XR at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.